4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline

4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is a building block and synthetic intermediate.^1,2,3,4,5 It has been used as a precursor in the synthesis of receptor tyrosine kinase (RTK) inhibitors, dual RTK and histone deacetylase (HDAC) inhibitors, and anticancer compounds.^1,2,3 It is also a synthetic intermediate in the synthesis of EGFR inhibitors, including erlotinib (Item No. 10483), with antiproliferative activity.^4,5

WARNING This product is not for human or veterinary use.

1. Pandey, A., Volkots, D.L., Seroogy, J.M., et al. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J. Med. Chem. 45(17), 3772-3793 (2002).

2. Li, W.W., Wang, X.Y., Zheng, R.L., et al. Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3-morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo. J. Med. Chem. 55(8), 3852-3866 (2012).

3. Zhang, X., Su, M., Chen, Y., et al. The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors. Molecules 18(6), 6491-6503 (2013).

4. Liu, Z., Wang, L., Feng, M., et al. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers. Bioorg. Chem. 77, 593-599 (2018).

5. Knesl, P., Röseling, D., and Jordis, U. Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: Tandutinib, erlotinib and gefitinib. Molecules 11(4), 286-297 (2006).